Nath Bio-Genes (India) Ltd - 537291 - Outcome of Board Meeting
Outcome of Board Meeting30-05-2019
Nath Bio-Genes (India) Ltd - 537291 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report23/05/2019 3 Name of the Certifying Firm NEHA P AGRAWAL 4 Name of the Certifying Individual NEHA P AGRAWAL 5Membership TypeFCS 6 Membership Number 7350 7 CP No. 8048 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO25-05-2019
Nath Bio-Genes (India) Ltd - 537291 - Closure of Trading Window
Closure of Trading Window21-05-2019
Nath Bio-Genes (India) Ltd - 537291 - Board Meeting Intimation for Board Meeting Intimation For Audited Financial Results For The Quarter And Financial Year End 31St March 2019
Nath Bio-Genes (India) Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2019 ,inter alia, to consider and approve Board Meeting Intimation for Audited financial results for the quarter and financial year end 31st March 201921-05-2019
Nath Bio-Genes (India) Ltd - 537291 - Revised Compliance Certificate Under Regulation 40 (10)
Revised Compliance Certificate Under Regulation 40 (10)08-05-2019
Nath Bio-Genes (India) Ltd - 537291 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance pursuant to regulation 39(3) of SEBI (LODR) Regulation, 201503-05-2019
Nath Bio-Genes (India) Ltd - 537291 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayNath Bio-Genes (India) Ltd 2CININE448G01010 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY BBB 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Dhiraj Rathi Designation: Company Secretary EmailId: investor@nathbiogenes.com Name of the Chief Financial Officer: Devinder Khurana Designation: Chief Financial Officer EmailId: khurana@biogenes.in Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.30-04-2019
Nath Bio-Genes (India) Ltd - 537291 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tingli Finvest Pvt Ltd26-04-2019
Nath Bio-Genes (India) Ltd - 537291 - Compliance Certificate For The Half Year Ended 31St March 2019
Compliance Certificate for the half year ended 31st March 201925-04-2019